After years of setbacks, Johnson & Johnson's ($JNJ) Yondelis finally has its shot at some U.S. sales. The drug won its sought-after FDA approval Friday--not in ovarian cancer as previously hoped, but as a treatment for soft-tissue sarcoma, which otherwise has few treatment options. Just what the FDA nod means in terms of sales remains to be seen--more than a decade ago, it was pegged as a potential blockbuster--but if the European market is any indication, uptake won't break any records.

http://www.fiercepharmamarketing.com/story/jjs-yondelis-finally-captures-fda-nod-path-big-sales-could-be-steep/2015-10-26